Did you know?

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to …NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Atai Life Sciences (NASDAQ:ATAI) closed at $1.06, down from prior weeks’ closings at $1.3, $1.28, $1.39 and $1.29. Incannex Healthcare (NASDAQ:IXHL) closed at $0.99, up from prior week’s close ...Nov 14, 2023 · NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...He was an early stakeholder in Atai Life Sciences (NASDAQ:ATAI), a startup with 10 psychedelic programs in the works and that count Peter Thiel as one of its primary investors.Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Atai Life Sciences N.V. (NASDAQ:ATAI) AVROBIO, Inc. (NASDAQ:AVRO) Axsome Therapeutics, Inc. (NASDAQ:AXSM) (communicated in its earnings release a potential delay in approval of its major ...Nov 14, 2023 · The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ... NEW YORK and BERLIN, Aug. 10, 2023-- atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2023 ...NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in the first quarter of 2023.NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...ATAI Life Sciences Stock (NASDAQ:ATAI), Guidance and Forecast benzinga.com - August 13 at 4:19 AM: ATAI Life Sciences Stock (NASDAQ:ATAI), Short Interest Report benzinga.com - August 12 at 11:19 PM: ATAI Life Sciences (ATAI) Receives a Buy from Berenberg Bank markets.businessinsider.com - August 11 at 5:09 PMGet ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...Oct 2, 2023 · NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release. Ticker Symbol: ATAI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $15.00: CIK Code: 0001840904: CUSIP Number: N0731H103 ...Dec 23, 2022 · NEW YORK and BERLIN, Dec. 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical stage biopharmaceutical company aiming to transform the ... Find the latest analyst research for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Mar 6, 2023 · NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... Atai Life Sciences (NASDAQ:ATAI) is one of the leading biotech companies discovering and developing treatments derived from psychedelic compounds. Atai already has an MDMA-derived drug in its ...Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Cash, cash ...Net loss attributable to ATAI Life Sciences N.V. stockholders $ (45,NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life atai Impact, the philanthropic program of atai Life Sciences (NASDAQ: ATAI) and the Multidisciplinary Association for Psychedelic Studies (MAPS) recently announced a $500,000 donation from atai ...ATAI ATAI Life Sciences. Close 12/01 16:00 ET. 1.120. +0.080 +7.69%. High 1.150 ... (NASDAQ:ATAI) shares closed up 4.67% at $1.12Mind Medi. Benzinga11-23 04:30 ET. NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) - Jan 18, 2022 ... In December, it was announced that atai would be added to the Nasdaq's prestigious biotechnology index. ... Atai Life Sciences Has Been Selected ...Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021. senior director of external affairs @ atai life scien

ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.4 days ago ... Atai Life Sciences N.V.'s stock symbol is ATAI and currently trades under NASDAQ. It's current price per share is approximately $1.12. How much ...Sep 21, 2021 · NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...

For ATAI Life Sciences NV (NASDAQ:ATAI), Canaccord Genuity initiated coverage, by setting the current rating at Buy. The stock has a 52-week-high of $22.91 and a 52-week-low of $16.50.(NASDAQ: KTTA), COMPASS Pathways plc (NASDAQ: CMPS), Field Trip Health Ltd. (NASDAQ: FTRP) (TSX: FTRP), Cybin Inc. (NYSE: CYBN), atai Life Sciences (NASDAQ: ATAI). Grand View Research continued with: “Presence of strong pipeline products by major pharmaceutical companies … are expected to accelerate market …For ATAI Life Sciences NV (NASDAQ:ATAI), Canaccord Genuity initiated coverage, by setting the current rating at Buy. The stock has a 52-week-high of $22.91 and a 52-week-low of $16.50.…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. ATAI's stock price has decreased by -68.7% in the past year . Possible cause: The average trading volume of ATAI on November 29, 2023 was 536.92K sh.